CO7310521A2 - Composición farmaceútica que tiene fluidez mejorada, agente medicional, y método para la producción y uso del mismo - Google Patents

Composición farmaceútica que tiene fluidez mejorada, agente medicional, y método para la producción y uso del mismo

Info

Publication number
CO7310521A2
CO7310521A2 CO15003855A CO15003855A CO7310521A2 CO 7310521 A2 CO7310521 A2 CO 7310521A2 CO 15003855 A CO15003855 A CO 15003855A CO 15003855 A CO15003855 A CO 15003855A CO 7310521 A2 CO7310521 A2 CO 7310521A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
improved fluidity
production
octylphenyl
propane
Prior art date
Application number
CO15003855A
Other languages
English (en)
Inventor
Alexander Vasilievich Ivachtchenko
Alexander Viktorovich Demin
Original Assignee
Alla Chem Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49446598&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7310521(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alla Chem Llc filed Critical Alla Chem Llc
Publication of CO7310521A2 publication Critical patent/CO7310521A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/074—Filling capsules; Related operations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se encuentra relacionada al campo de loscompuestos farmacéuticos, en particular, a una composiciónfarmacéutica sólida que comprende 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol o sal farmacéuticamenteaceptable del mismo, estabilizador, lubricante y rellenador;un método para la preparación de una composiciónfarmacéutica, a medicamentos para supresión inmune ytratamiento de la esclerosis múltiple. El 2-Amino-2-[2-(4-octilfenil)etil]propano-1,3-diol representa un moduladorinmune, el cual produce la redistribución de linfocitos delfluido sanguíneo a tejidos linfoides secundarios queconllevan a la supresión inmune. La invención proporciona unadistribución uniforme del ingrediente activo en lacomposición sólida, alta estabilidad y fluidez mejorada de lacomposición farmacéutica sólida. Debida a la fluidez mejoradaLas composiciones sugeridas en la invención pueden ser usadosen equipos automáticos.
CO15003855A 2012-07-11 2015-01-08 Composición farmaceútica que tiene fluidez mejorada, agente medicional, y método para la producción y uso del mismo CO7310521A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2012129101/15A RU2496486C1 (ru) 2012-07-11 2012-07-11 Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение

Publications (1)

Publication Number Publication Date
CO7310521A2 true CO7310521A2 (es) 2015-06-30

Family

ID=49446598

Family Applications (1)

Application Number Title Priority Date Filing Date
CO15003855A CO7310521A2 (es) 2012-07-11 2015-01-08 Composición farmaceútica que tiene fluidez mejorada, agente medicional, y método para la producción y uso del mismo

Country Status (22)

Country Link
US (1) US9370576B2 (es)
EP (1) EP2873416B1 (es)
JP (1) JP6093015B2 (es)
KR (1) KR20150036228A (es)
CN (1) CN104487063B (es)
AP (1) AP2014008171A0 (es)
BR (1) BR112015000544A2 (es)
CL (1) CL2015000052A1 (es)
CO (1) CO7310521A2 (es)
EA (1) EA027712B1 (es)
GE (1) GEP201606571B (es)
IL (1) IL236562A0 (es)
IN (1) IN2015DN00130A (es)
MA (1) MA37693B1 (es)
MX (1) MX2015000467A (es)
PE (1) PE20150632A1 (es)
RU (1) RU2496486C1 (es)
SG (1) SG11201500178QA (es)
TN (1) TN2015000006A1 (es)
UA (1) UA113216C2 (es)
WO (1) WO2014011083A2 (es)
ZA (1) ZA201409481B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110398A1 (en) 2013-01-10 2014-07-17 Edh Us Llc Ball spin rate measurement
RU2611415C1 (ru) * 2015-11-17 2017-02-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ТЕРАПЕВТИЧЕСКИМ ЭФФЕКТОМ В ОТНОШЕНИИ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ (Варианты)
WO2020005189A2 (en) * 2018-06-27 2020-01-02 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions comprising teriflunomide

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
SK282225B6 (sk) 1995-12-28 2001-12-03 Welfide Corporation Použitie 2-amino-2[2-(4-oktylfenyl)etyl]-propán-1,3-diolu alebo jeho farmaceuticky prijateľnej adičnej soli s kyselinou na výrobu farmaceutického prostriedku
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
RU2358717C2 (ru) 2002-05-16 2009-06-20 Новартис Аг Применение средств, связывающих edg-рецептор, в лечении ракового заболевания
DE122011100047I1 (de) * 2003-04-08 2011-12-15 Mitsubishi Tanabe Pharma Corp Feste pharmazeutische darreichungsformen mit einemS1P rezeptoragonisten und einem zuckeralkohol.
EP1663188B1 (en) * 2003-09-12 2016-08-10 Newron Sweden AB Treatment of disorders of the nervous system
RU2402324C2 (ru) 2004-07-30 2010-10-27 Новартис Аг Композиции на основе соединений 2-амино-1,3-пропандиола
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
MXPA05008573A (es) 2005-08-12 2007-02-12 Leopoldo Espinosa Abdala Composicion de isoflavonas para tratamiento de los sintomas y trastornos fisiologicos de la menopausia.
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP3103448B1 (en) * 2006-09-26 2019-07-03 Novartis Ag Pharmaceutical compositions comprising an s1p modulator
WO2009048993A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
EP2560621A1 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH Fingolimod in the form of a solid solution
CA2797551A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Melt-granulated fingolimod

Also Published As

Publication number Publication date
TN2015000006A1 (en) 2016-06-29
CN104487063A (zh) 2015-04-01
IL236562A0 (en) 2015-02-26
IN2015DN00130A (es) 2015-05-29
JP6093015B2 (ja) 2017-03-08
GEP201606571B (en) 2016-11-10
MX2015000467A (es) 2015-06-05
WO2014011083A2 (ru) 2014-01-16
PE20150632A1 (es) 2015-05-20
UA113216C2 (xx) 2016-12-26
SG11201500178QA (en) 2015-03-30
EP2873416B1 (en) 2017-04-26
EP2873416A4 (en) 2016-03-16
CN104487063B (zh) 2017-05-10
BR112015000544A2 (pt) 2017-10-24
US20150335754A1 (en) 2015-11-26
WO2014011083A3 (ru) 2014-03-06
ZA201409481B (en) 2016-02-24
EP2873416A2 (en) 2015-05-20
CL2015000052A1 (es) 2015-09-04
EA027712B1 (ru) 2017-08-31
KR20150036228A (ko) 2015-04-07
US9370576B2 (en) 2016-06-21
AP2014008171A0 (en) 2014-12-31
EA201500096A1 (ru) 2015-05-29
JP2015522068A (ja) 2015-08-03
RU2496486C1 (ru) 2013-10-27
MA37693B1 (fr) 2017-01-31
MA37693A1 (fr) 2016-06-30

Similar Documents

Publication Publication Date Title
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
CL2016001874A1 (es) Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras.
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
CL2013002810A1 (es) Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple.
BR112018011266A2 (pt) ?composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica?
BR112018014027A2 (pt) composições e métodos para administração intravenosa de 2-bromo-1-(3,3-dinitroazeditin-1-il)etanona
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
MA39443A1 (fr) Nouvelle formulation de méloxicam
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
EA201590193A1 (ru) Препараты лаквинимода без подщелачивающего агента
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112019008239A2 (pt) formulações aquosas, estáveis, injetáveis de capsaicina e uso médicos dos mesmos
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
CO7310521A2 (es) Composición farmaceútica que tiene fluidez mejorada, agente medicional, y método para la producción y uso del mismo
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
BR112016009214A8 (pt) uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
AR088453A1 (es) Regimen de dosificacion del agonista o modulador del receptor de s1p
ES2422563A1 (es) Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma